Company profile
NURIX THERAPEUTICS, INC.
NASDAQ:NRIXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BEXOBRUTIDEG | phase3 | — | 6 | active |
| ZELEBRUDOMIDE | phase1 | — | 1 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06593457 | phase1 | completed | 2024-08-20 | 2024-10-29 | Nurix Therapeutics, Inc. | A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects |
| NCT06717269 | phase1 | completed | 2024-11-30 | 2026-05-01 | Nurix Therapeutics, Inc. | A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers |
| NCT05107739 | phase1 | terminated | 2021-12-22 | 2023-05-09 | Nurix Therapeutics, Inc. | A Study of DeTIL-0255 in Adults With Advanced Malignancies |
| NCT05107674 | phase1 | recruiting | 2021-09-29 | 2026-08-31 | Nurix Therapeutics, Inc. | A Study of NX-1607 in Adults With Advanced Malignancies |
| NCT04830137 | phase1 | recruiting | 2021-05-05 | 2026-05-01 | Nurix Therapeutics, Inc. | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies |
FDA applications (0)
No records yet.